Vor Biopharma Inc.(VOR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
VOR Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Vor Biopharma Inc. (VOR), a Healthcare sector company. VOR is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Vor Biopharma Inc. reports net income of $-62.8M, free cash flow of $-25.5M. Top institutional holders of VOR by reported 13-F value include TCG Crossover Management, FMR, FCPM III SERVICES B.V., based on the most recent SEC filings. VOR trades on the Nasdaq exchange and files with the SEC under CIK 1817229. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VOR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vor Biopharma Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-62.8M
Free Cash Flow
Q2 2026
$-25.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-495.3% YoYOperating Income
-206.7% YoYEPS (Diluted)
-107.2% YoYTotal Assets
+224.8% YoYOp. Cash Flow
-43.2% YoYFree Cash Flow
-43.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-696.0M -495.3% | $-116.9M +0.8% | $-117.9M -28.0% | $-92.1M -33.7% | $-68.9M -59.0% | $-43.3M |
| Operating Income | $-371.6M -206.7% | $-121.2M +3.8% | $-126.0M -34.9% | $-93.4M -35.4% | $-69.0M -59.2% | $-43.4M |
| EPS (Diluted) | $-70.50 -107.2% | $-34.03 -1844.6% | $-1.75 +24.9% | $-2.33 -11.0% | $-2.10 | — |
| Total Assets | $464.1M +224.8% | $142.9M -27.9% | $198.1M -33.8% | $299.4M +23.4% | $242.6M +219.6% | $75.9M |
| Operating Cash Flow | $-142.7M -43.2% | $-99.7M +0.6% | $-100.3M -17.8% | $-85.1M -23.1% | $-69.1M -90.5% | $-36.3M |
| Free Cash Flow | $-143.7M -43.8% | $-99.9M +1.5% | $-101.4M -8.3% | $-93.6M -28.2% | $-73.0M -80.6% | $-40.5M |
Get alerted when VOR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Vor Biopharma Inc. including:
Top Institutional Holders of VOR
TCG Crossover Management, LLC
$104.4M5,673,078 shFMR LLC
$90.8M4,932,149 shFCPM III SERVICES B.V.
$75.8M4,117,354 shBlackRock, Inc.
$63.8M3,468,107 shVR Adviser, LLC
$56.0M3,041,719 shSTATE STREET CORP
$48.2M2,616,336 shFrazier Life Sciences Management, L.P.
$46.8M2,543,939 shRA CAPITAL MANAGEMENT, L.P.
$44.2M2,402,095 shVANGUARD CAPITAL MANAGEMENT LLC
$38.4M2,084,328 shCaligan Partners LP
$35.4M1,925,066 sh
| Fund | Value | Shares |
|---|---|---|
| TCG Crossover Management, LLC | $104.4M | 5,673,078 |
| FMR LLC | $90.8M | 4,932,149 |
| FCPM III SERVICES B.V. | $75.8M | 4,117,354 |
| BlackRock, Inc. | $63.8M | 3,468,107 |
| VR Adviser, LLC | $56.0M | 3,041,719 |
| STATE STREET CORP | $48.2M | 2,616,336 |
| Frazier Life Sciences Management, L.P. | $46.8M | 2,543,939 |
| RA CAPITAL MANAGEMENT, L.P. | $44.2M | 2,402,095 |
| VANGUARD CAPITAL MANAGEMENT LLC | $38.4M | 2,084,328 |
| Caligan Partners LP | $35.4M | 1,925,066 |
More Healthcare Companies
View all Healthcare →Put VOR on your watchlist
Track score changes the day Vor Biopharma Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is VOR a good stock to buy?
13F Pro's AI-powered analysis of Vor Biopharma Inc. (VOR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VOR are available on the VOR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VOR is classified as a small company.
Which hedge funds own VOR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VOR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Vor Biopharma Inc.'s investment landscape.